Document:

<PAGE>
                                                                    Exhibit 10.5

--------------------------------------------------------------------------------
          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.
--------------------------------------------------------------------------------

                                LICENSE AGREEMENT

                                     BETWEEN

                           CRITICAL THERAPEUTICS, INC.

                                       AND

               NORTH SHORE - LONG ISLAND JEWISH RESEARCH INSTITUTE

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<S>         <C>                                                                                                 <C>
ARTICLE 1.  DEFINITIONS...........................................................................................1
   1.1.       "Affiliate".........................................................................................1
   1.2.       "Effective Date"....................................................................................1
   1.3.       "Field".............................................................................................1
   1.4.       "First Commercial Sale".............................................................................1
   1.5.       "License Term"......................................................................................1
   1.6.       "Net Sales".........................................................................................2
   1.7.       "NS HMG-l Technology"...............................................................................2
   1.8.       "NS HMG-1 Patent Rights"............................................................................2
   1.9.       "NS Valid Patent Claim".............................................................................2
   1.10.      "Product(s)"........................................................................................2
ARTICLE 2.  LICENSE GRANT.........................................................................................2
   2.1.       License Grant.......................................................................................2
   2.2.       Government Rights...................................................................................3
   2.3.       Retention of NS Rights..............................................................................3
ARTICLE 3.  LICENSE FEES, MILESTONES AND ROYALTIES................................................................3
   3.1.       Down Payment........................................................................................3
   3.2.       Milestone Payments..................................................................................3
   3.3.       Royalty Payments....................................................................................4
              3.3.1.       Royalty Reports and Payments...........................................................4
              3.3.2.       One Royalty............................................................................4
              3.3.3.       Incorporation of Other Products........................................................5
              3.3.4.       Third-Party Licenses...................................................................5
   3.4.       Minimum Royalties...................................................................................5
   3.5.       Sublicense Income...................................................................................5
ARTICLE 4.  PATENTS...............................................................................................5
   4.1.       CTI Authority.......................................................................................5
   4.2.       Patent Expenses.....................................................................................6
   4.3.       Right of NS to be Informed..........................................................................6
   4.4.       NS Rights...........................................................................................6
   4.5.       Enforcement of NS Patent Rights.....................................................................6
ARTICLE 5.  CONFIDENTIALITY AND PUBLICATION.......................................................................7
   5.1.       Non-Disclosure Obligations..........................................................................7
   5.2.       Release of Obligations..............................................................................7
   5.3.       Publications........................................................................................7
ARTICLE 6.  REPRESENTATIONS AND WARRANTIES........................................................................7
   6.1.       Authorization.......................................................................................7
   6.2.       NS HMG-1 Patent Rights..............................................................................8
   6.3.       Remedies............................................................................................8
ARTICLE 7.  TERM AND TERN LUNATION................................................................................8
   7.1.       Expiration..........................................................................................8
   7.2.       Termination for Cause...............................................................................8
   7.3.       Effect of Termination...............................................................................8
ARTICLE 8.  INDEMNIFICATION AND INSURANCE.........................................................................8
   8.1.       Indemnity...........................................................................................8
</TABLE>

                                       i
<PAGE>

<TABLE>
<S>         <C>                                                                                                 <C>
   8.2.       Insurance...........................................................................................9
ARTICLE 9.  MISCELLANEOUS.........................................................................................9
   9.1.       Force Majeure.......................................................................................9
   9.2.       Assignment..........................................................................................9
   9.3.       Severability........................................................................................9
   9.4.       Notices............................................................................................10
   9.5.       Applicable Law.....................................................................................10
   9.6.       Dispute Resolution.................................................................................10
   9.7.       Entire Agreement...................................................................................10
   9.8.       Headings...........................................................................................10
   9.9.       Independent Contractors............................................................................10
   9.10.      Waiver.............................................................................................11
   9.11.      Counterparts.......................................................................................11
   9.12.      Use of Names.......................................................................................11
</TABLE>

                                       ii
<PAGE>

                                LICENSE AGREEMENT

      This License Agreement (the "License Agreement") is made between Critical
Therapeutics, Inc. (formerly known as Medicept, Inc.), a Delaware corporation
("CTI") and North Shore - Long Island Jewish Research Institute, a New York
non-profit corporation ("NS").

                                    RECITALS

      WHEREAS, NS owns or controls certain patent rights and technology relating
to inhibitors and antagonists of High Mobility Group 1 Protein (HMG-1) and is
willing to license CTI under its patent rights and technology; and,

      WHEREAS, CTI desires to be licensed under the NS patent rights and
technology relating to inhibitors and antagonists of HMG-1;

      NOW, THEREFORE, in consideration of the premises and of the covenants
herein contained, CTI and NS mutually agree as follows:

                             ARTICLE 1. DEFINITIONS

      For purposes of this License Agreement, the terms defined in this Article
shall have the meanings specified below:

      1.1. "Affiliate" shall mean any corporation or other entity which
controls, is controlled by, or is under common control with a party to this
License Agreement. A corporation or other entity shall be regarded as in control
of another corporation or entity if it owns or directly or indirectly controls
more than fifty percent (50%) of the voting stock or other ownership interest of
the other corporation or entity, or if it possesses, directly or indirectly, the
power to direct or cause the direction of the management and policies of the
corporation or other entity or the power to elect or appoint fifty percent (50%)
or more of the members of the governing body of the corporation or other entity.

      1.2. "Effective Date" of this License Agreement shall be July 1, 2001.

      1.3. "Field" shall mean the therapeutic, prophylactic and/or diagnostic
use of inhibitors and/or antagonists of HMG-1 and related proteins (that is,
proteins that contain the HMG boxes), including, but not limited to, antibodies
and fragments thereof, inhibitors and antagonists thereof.

      1.4. "First Commercial Sale" of any Product shall mean the first sale for
use or consumption by the general public of such Product in a country.

      1.5. "License Term" shall mean the later of ten years from the First
Commercial Sale for each Product or the last to expire of the NS Patent Rights
covering each Product on a country-by-country basis.

<PAGE>

      1.6. "Net Sales" shall mean the gross amount billed or invoiced and
received by CTI or its Affiliates (but not sublicensees) for sale or other
disposition of Product(s) to independent third parties, less the following: (i)
customary trade, quantity, or cash discounts to the extent actually allowed and
taken; (ii) amounts repaid and credited by reason of rejection or return; and
(iii) to the extent separately stated on purchase orders, invoices, or other
documents of sale, any taxes or other governmental charges levied on the
production, sale, transportation, delivery, or use of the Product that is paid
by or on behalf of CTI or its Affiliates. Net Sales will be determined from the
books and records of CTI and its Affiliates maintained in accordance with
generally accepted accounting principles, consistently applied.

      1.7. "NS HMG-l Technology" shall mean all information, data, know-how,
materials (including biological materials), inventions (whether patentable or
not), models, screens, trade secrets, patents, patent applications, and other
intellectual property of any kind, whether patented or unpatented, owned and/or
controlled by NS in the Field, as of the Effective Date, and related to a method
to treat or diagnose diseases caused by an excess of HMG-1 using inhibitors or
antagonists to inhibit the activity of HMG-1.

      1.8. "NS HMG-1 Patent Rights" shall mean those patent applications listed
in attached Schedule 1.8 together with any continuations, continuations-in-part,
divisionals, non-provisional applications, patents which are granted based on
any of the aforementioned applications and any reissues, renewals,
reexaminations, substitutions or extensions thereof and any foreign counterparts
to any of the foregoing.

      1.9. "NS Valid Patent Claim" shall mean either (a) a claim of an issued
and unexpired patent included within the NS HMG-1 Patent Rights, which has not
been held permanently revoked, unenforceable or invalid by a decision of a court
or other governmental agency of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal, and which has not been admitted
to be invalid or unenforceable through reissue, disclaimer or otherwise or (b) a
claim of any pending patent application included within the NS HMG-1 Patent
Rights, which claim was filed in good faith and has not been abandoned or
finally disallowed without the possibility of appeal or refiling of said
application.

      1.10. "Product(s)" shall mean any product or service in the Field: (1)
covered by an NS Valid Patent Claim; (2) made by a process covered by an NS
Valid Patent Claim; or (3) the manufacture, use, practice or sale of which
includes the use of NS HMG-1 Technology.

      1.11. "Territory" shall mean the entire world.

                            ARTICLE 2. LICENSE GRANT

      2.1. License Grant. NS hereby grants to CTI and its Affiliates a
royalty-bearing, sole and exclusive license in the Territory, with the right to
sublicense, to make, have made, use, offer for sale, sell and/or import
Product(s) under NS HMG-1 Technology and NS HMG-1 Patent Rights. CTI shall
provide NS with a full and complete copy of any sublicense granted pursuant to
this Agreement and any documents evidencing the consideration to be paid to CTI
or its Affiliates relating to the grant of any such sublicense within thirty
(30) days of execution thereof by CTI. CTI acknowledges and agrees that its
exclusive license under any patent that may issue

                                       2
<PAGE>

from U.S.S.N. [**], or claim priority to it, is subject to any rights of joint
owners of such patent application.

      2.2. Government Rights. CTI and NS mutually acknowledge that the United
States Government, as a matter of statutory right under 35 U.S.C. Sections
200-212, holds or may hold a non-exclusive license and certain other rights
under NS HMG-1 Patent Rights or related inventions made as a consequence of
research whose funding includes funds supplied by the U.S. Government. NS
warrants that to the extent it is aware of any funding supplied by the U.S.
Government, the details of such funding shall be provided to CTI prior to
execution of this License Agreement. The term "sole and exclusive" license shall
be understood to be subject to the rights of the U.S. Government without any
effect on the parties' remaining obligations, as set forth in this License
Agreement.

      2.3. Retention of NS Rights. Notwithstanding the exclusive rights granted
to CTI pursuant to Article 2.1, NS shall retain the right to make and use
Products in its own laboratories solely for non-commercial, scientific purposes
and for continued non-commercial research.

                ARTICLE 3. LICENSE FEES, MILESTONES AND ROYALTIES

      3.1. Down Payment. CTI shall pay to NS:

            (a) Fifty Thousand Dollars ($50,000.00) within sixty (60) days after
the Effective Date; and

            (b) Fifty Thousand Dollars ($50,000.00) within thirty (30) days of
NS providing to CTI copies of documents evidencing that NS is rightfully
designated as the only Applicant on Patent Cooperation Treaty Application Number
[**] (e.g., a Change of Applicant form signed by NS and The Picower Institute
for Medical Research naming NS as the Applicant), or other convincing evidence
that NS is the sole owner of the foreign patent rights for inventions described
in U.S. Applications Serial Numbers [**] and [**], provided such evidence is
delivered to CTI within five (5) years from the Effective Date. If NS obtains
such evidence within such period, NS agrees to provide the evidence promptly to
CTI and CTI agrees to make such payment. If NS does not obtain and provide the
above evidence within five (5) years from the Effective Date, the definition of
Territory in Article 1.1 shall automatically be changed from "the entire world"
to "the United States" and all foreign patent rights shall be deleted from the
definition of NS HMG-1 Patent Rights.

      3.2. Milestone Payments. CTI and its Affiliates shall additionally pay to
NS the following milestone payments:

            (a) for Products covered by an NS Valid Patent Claim or made by a
process covered by an NS Valid Claim:

                  (i) One Hundred Seventy Five Thousand Dollars ($175,000.00)
upon the [**] covered by an NS Valid Patent Claim; and

                  (ii) [**] Dollars ($[**]) upon the [**] covered by an NS Valid
Patent Claim.

                                       3
<PAGE>

            (b) for Products not covered by an NS Valid Patent Claim:

                  (i) [**] Dollars ($[**]) upon the [**]; and

                  (ii) [**] Dollars ($[**]) upon [**].

      3.3. Royalty Payments. CTI and its Affiliates shall additionally pay
royalties to NS of:

            (a) For Products covered by an NS Valid Patent Claim or made by a
process covered by an NS Valid Claim:

                  (i) [**] percent ([**]%) on annual Net Sales by CTI or its
Affiliates up to [**] Dollars ($[**]); and

                  (ii) [**] percent ([**]%) on annual Net Sales by CTI or its
Affiliates in excess of [**] Dollars ($[**]);

            (b) For Products not covered by an NS Valid Patent Claim:

                  (i) [**] percent ([**]%) on annual Net Sales by CTI or its
Affiliates up to [**] Dollars ($[**]); and

                  (ii) [**] percent ([**]%) on annual Net Sales by CTI or its
Affiliates in excess of [**] Dollars ($[**]).

            3.3.1. Royalty Reports and Payments. During the License Term and
following the First Commercial Sale of a Product in each country in the
Territory, CTI and its Affiliates shall furnish to NS quarterly reports within
sixty (60) days of the end of each calendar quarter, showing, on a
country-by-country basis, the gross sales of all Products sold by CTI and its
Affiliates during the reporting period, the calculation of Net Sales from such
gross sales, all consideration received by CTI and/or its Affiliates from
sub-licensees in connection with the grant of any sub-licenses pursuant to this
Agreement and the amount of any payments due to NS. Such quarterly reports shall
be accompanied by payment of the royalty amount or other payments due for that
calendar quarter. CTI and/or its Affiliates shall maintain complete and accurate
books of account and records showing Net Sales and amounts received from
sub-licensees. Such books and records shall be open to inspection, in
confidence, by NS during usual business hours, by an independent certified
public accountant to whom CTI has no reasonable objection, for two (2) years
after the calendar year to which they pertain, for the purpose of verifying the
accuracy of the payments made to NS pursuant to this Agreement. CTI and/or its
Affiliates shall use commercially reasonable efforts to require any
sub-licensees hereunder to maintain such books and allow such inspection by NS
and shall, on request, disclose such information to NS as part of such
inspection. Inspection shall be at NS's sole expense, shall be reasonably
limited to those matters related to the payment obligations under this
Agreement, and shall be permitted no more than once per calendar year.

            3.3.2. One Royalty. Royalty payments pursuant to Article 3.3 shall
be due only on the first sale or other disposition of Product(s) to an
independent third party.

                                       4
<PAGE>

            3.3.3. Incorporation of Other Products. In the event that a Product
is marketed as part of a bundle, system or kit that incorporates or includes
other products, Net Sales will be computed using the average net selling price
of the components when sold separately. If any Product is sold only as part of a
bundle, system or kit and is not sold separately, then Net Sales will include
only that part of such sale reasonably allocable to the Product. In making such
allocation, primary consideration will be given to the added value provided by
the Product as compared to the value of the bundle, system or kit if sold
without it.

            3.3.4. Third-Party Licenses. In the event that CTI or its Affiliates
licenses one or more technologies from third-parties in order to develop and
market Product(s), the amount of royalty payments due to NS under Article 3.3
shall be reduced by an amount equal to [**] percent ([**]%) of the payments due
to third-parties; provided, that in no event shall the royalty payments due to
NS hereunder be reduced below [**] percent ([**]%) under Article 3.3(a) and
below [**] percent ([**]%) under Article 3.3(b) of Net Sales by CTI or its
Affiliates. This paragraph will not apply to any patents or patent applications
issuing from U.S.S.N. [**]. In regard to U.S.S.N. [**] and any further patent
applications and patents claiming priority to it, NS shall use its reasonable
best efforts to obtain Inter-Institutional Agreements (IIAs) with all non-NS
co-owners of this application under which NS shall have the right to grant
exclusive license rights to CTI from such non-NS co-owners. If NS is successful
in obtaining such IIAs, NS shall promptly grant to CTI exclusive license rights
from the non-NS owners of said patent applications and/or patents.

      3.4. Minimum Royalties. CTI or its Affiliates, in order to maintain the
licenses granted in this License Agreement, agrees to pay to NS, beginning on
the sixth anniversary of the Effective Date and each anniversary thereafter, the
following amounts:

<TABLE>
<CAPTION>
YEARS                            AMOUNT
-----                            ------
<S>                              <C>
6-10                             [**] Dollars ($[**])
11 and thereafter                [**] Dollars ($[**])
</TABLE>

The amounts due under this clause shall be paid to NS on the anniversary of the
Effective Date in each of the above years and shall be creditable against future
royalties due to NS. CTI's failure to make the payments required by this Section
3.4, after written notice of such failure and an opportunity to cure, shall
entitle NS to terminate this Agreement pursuant to Section 7.2.

      3.5. Sublicense Income. In the event that CTI and/or its Affiliates grants
one or more sublicenses under NS HMG-1 Technology and/or NS HMG-1 Patent Rights,
CTI shall pay or cause its Affiliates to pay, as the case may be, to NS an
amount equal to [**] percent ([**]%) of all consideration in any form received
by CTI and/or its Affiliates for the sublicense(s).

                               ARTICLE 4. PATENTS

      4.1. CTI Authority. CTI shall have primary responsibility for filing,
prosecuting, issuing, maintaining and defending the NS HMG-1 Patent Rights in
the United States and worldwide, employing patent counsel of its choice.
Initially, CTI's choice for patent counsel is the firm of Hamilton, Brook, Smith
& Reynolds, P.C., Lexington, Massachusetts, for which NS

                                       5
<PAGE>

grants its approval. If CTI decides to retain a different or additional patent
counsel in the future, NS shall have the right to approve CTI's selection of a
different or additional patent counsel, such approval not to be unreasonably
withheld. Patent counsel selected by CTI shall treat NS as its client and the
owner of the HMG-1 Patent Rights.

      4.2. Patent Expenses. CTI agrees to bear the cost for all patent work
performed pursuant to Article 4.1 after the Effective Date. Bills for such work
may be rendered to NS, in which case CTI agrees to promptly reimburse NS for its
expenses in this regard. Alternatively, for convenience, bills for work
performed pursuant to Article 4.1 may be sent directly to CTI for payment, with
a copy to NS. In regard to reasonable patent expenses incurred by NS prior to
the Effective Date, CTI agrees to reimburse NS for such expenses for U.S.
Applications Serial Nos. [**] and [**] up to a maximum reimbursement of [**]
Dollars ($[**]) and for [**] of such expenses for U.S. Provisional Application
No. [**] up to a maximum reimbursement of [**] Dollars ($[**]) within sixty (60)
days of the Effective Date. In addition, CTI agrees to further reimburse NS for
its reasonable past patent expenses, as follows:

            (a)   Such expenses for International Patent Application [**] up to
                  a maximum of [**] Dollars ($[**]) within sixty (60) days of NS
                  securing and evidencing sole ownership of the aforementioned
                  PCT Application according to the provisions of Article 3.1(b);
                  and,

            (b)   The remaining [**] of its expenses for U.S. Provisional
                  Application No. [**] if NS is successful in obtaining the
                  right to grant exclusive rights to CTI from all joint owners
                  of the aforementioned Provisional Application and does grant
                  such rights, as provided in Article 3.3.4, such [**] share to
                  be limited to a maximum of [**] Dollars ($[**]) and to be
                  payable within sixty (60) days of the grant of such exclusive
                  rights to CTI.

      4.3. Right of NS to be Informed. For work performed by patent counsel
selected by CTI pursuant to Article 4.1, such patent counsel shall keep NS
apprised of the status of each of the patent applications and patents in the NS
HMG-1 Patent Rights and will consult with NS concerning the prosecution of such
patent applications. Such patent counsel will provide NS in a timely manner with
copies of all documents related to the filing, prosecution, issuance,
maintenance and/or defense of such applications or patents in the NS Patent
Rights.

      4.4. NS Rights. If CTI decides to abandon any application(s) or patent(s)
within the NS HMG-1 Patent Rights or declines to file and prosecute a patent
application for an invention within the NS HMG-1 Patent Rights that NS desires
to have filed and prosecuted, it agrees to provide NS with sufficient notice to
allow NS to assume filing and/or prosecution of the application(s) or
maintenance of the patent(s). If NS does make such assumption, CTI shall no
longer be licensed under those patent application(s) or patent(s).

      4.5. Enforcement of NS Patent Rights. If CTI or NS becomes aware of any
actual or potential infringement of the NS HMG-1 Patent Rights, it will notify
the other party and CTI and NS will subsequently confer and agree upon
appropriate action against such actual or potential infringement. If it is
decided to enforce the NS HMG-1 Patent Rights against such infringement, CTI
shall have the first right to do so and NS shall provide full cooperation at the
expense of

                                       6
<PAGE>

CTI. Any settlement or recovery received from any such proceeding shall be
divided [**] percent ([**]%) to CTI and [**] percent ([**]%) to NS after CTI
deducts from any such settlement or recovery its reasonable counsel fees and
out-of-pocket expenses relative to any such legal proceeding. If CTI decides not
to initiate legal proceedings against any such infringer, then NS shall have the
right to initiate such legal proceedings. Any settlement or recovery received
from any such proceeding shall be divided [**] percent ([**]%) to NS and [**]
percent ([**]%) to CTI after NS deducts from any such settlement or recovery its
reasonable counsel fees and out-of-pocket expenses relative to any such legal
proceeding.

                   ARTICLE 5. CONFIDENTIALITY AND PUBLICATION

      5.1. Non-Disclosure Obligations. During the License Term and for a period
of ten (10) years thereafter, both parties shall maintain in confidence, and use
only for purposes of this License Agreement, confidential information and data
received from the other party. Upon expiration or termination of this License
Agreement, all confidential information and data, and copies thereof, will be
returned to the transmitting party by the receiving party upon request of the
transmitting party.

      5.2. Release of Obligations. The obligations under Article 5.1 shall not
apply to any information or data that:

            (a) is or becomes publicly available;

            (b) is disclosed to the receiving party by a third party that is not
under an obligation to the other party to this License Agreement;

            (c) prior to disclosure to the other party, the receiving party was
already in possession of the information or data; or,

            (d) was independently developed by the receiving party without
breach of the obligations of Article 5.1.

      5.3. Publications. NS shall not publish any information which might
adversely affect the NS HMG-1 Patent Rights without prior written approval from
CTI after such information has been submitted to CTI at least thirty (30) days
prior to the intended date of submission for publication. CTI shall not
unreasonably withhold approval of such publication but does have the right to
request delay of the submission for a maximum period of forty-five (45) days to
allow for patent applications covering such information or data to be filed.
Nothing herein contained shall preclude NS from making required reports or
disclosures to the National Institutes of Health.

                   ARTICLE 6. REPRESENTATIONS AND WARRANTIES

      6.1. Authorization. Each party warrants and represents to the other that
it has the legal right and power to enter into this License Agreement, to fully
perform its obligations hereunder, and that it has not made nor will it make any
commitments to others in conflict with or in derogation of such rights or this
License Agreement. Except as otherwise disclosed, each party

                                       7
<PAGE>

further represents to the other that it is not aware of any legal obstacles,
including patent rights of others, which could prevent it from carrying out the
provisions of this License Agreement.

      6.2. NS HMG-1 Patent Rights. NS warrants and represents that it owns all
right, title and interest to NS HMG-1 Patent Rights except as specified on
attached Schedule 1.8 and that NS has not granted any other ownership, license,
option or other rights to the NS HMG-1 Patent Rights. NS further warrants and
represents that Schedule 1.8 is a complete list of all patent applications and
patents owned (solely or jointly with others) and/or controlled by NS and
relating to HMG-1 and antagonists thereof as of the Effective Date.

      6.3. Remedies. If pursuant to Article 3.1(b), the definition of Territory
in Article 1.1 is changed from "the entire world" to "the United States," such
change shall be deemed to be retroactive to the Effective Date. Until such
change or until the $50,000 specified in Article 3.1(b) has been paid, NS's
representation and warranties as to its ownership in the NS HMG-1 Patent Rights
shall be limited to the United States. The liability of NS for CTI's damages for
any breach of the warranties and representations contained in the Article will
be limited to reimbursement to CTI by NS of the total of all of the payments
received by NS pursuant to this License Agreement.

                        ARTICLE 7. TERM AND TERMINATION

      7.1. Expiration. Unless terminated earlier pursuant to Article 7.2 below,
the term of this License Agreement shall extend for the full License Term.

      7.2. Termination for Cause. Upon or after a breach of any material
provision of this License Agreement by a party (including non-timely payment of
any payment due to NS hereunder), the non-breaching party may terminate this
License Agreement by giving the breaching party thirty (30) days notice in
writing specifying the breach; providing, however, that such notice of
termination shall not be effective: (1) if the breaching party cures the
specified breach within such thirty (30) day period; or (2) if the specified
breach is not reasonably curable within such thirty (30) day period, and the
breaching party has commenced cure of such breach within the thirty (30) day
period and thereafter has proceeded diligently to cure such breach within a
reasonable time.

      7.3. Effect of Termination. Expiration or termination of this License
Agreement shall not relieve the parties of any obligation accruing prior to such
expiration or termination. Moreover, the provisions of Articles 5 and 6 shall
survive the expiration or termination of this License Agreement.

                    ARTICLE 8. INDEMNIFICATION AND INSURANCE

      8.1. Indemnity. CTI shall indemnify and hold NS harmless from and against
any liability, losses, damages, claims, costs and expenses (including reasonable
fees of attorneys and other professionals and court cost) arising from a product
liability claim, action or cause of action related to the sale of Products or an
act of infringement by CTI of a third party's patent, copyright or trademark in
connection with the manufacture, use, sale, storage or advertising of Products
except to the extent that such claims, demands, suits or causes of action are
based upon gross negligence or willful malfeasance by NS (hereafter collectively
called "Claim"). Subject

                                       8
<PAGE>

to the terms and conditions of this Agreement, CTI will have the primary
responsibility for defending against any Claim (whether arising under theories
of negligence, strict liability, tort, product liability or otherwise and
whether or not NS is named as a defendant in such claim, action or cause of
action).

      8.2. Insurance. In accordance with the provisions of Article 8.1 above,
CTI shall arrange for sufficient insurance and/or self-insurance coverage
commencing no later than the First Commercial Sale and, if possible, will name
NS as an additional insured.

                            ARTICLE 9. MISCELLANEOUS

      9.1. Force Majeure. Neither party shall be held liable or responsible to
the other party or be deemed to have defaulted under or breached this License
Agreement for failure or delay in fulfilling or performing any term of this
License Agreement when such failure or delay is caused by or results from cases
beyond the reasonable control of the affected party, including, but not limited
to, fire, floods, embargos, war, acts of war (whether war is declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God, or acts, omissions or delays in acting by any
Governmental authority for the other party.

      9.2. Assignment. This License Agreement may not be assigned or otherwise
transferred by either party without the written consent of the other party;
provided, however, that CTI and its Affiliates may, without such consent, assign
this License Agreement and its rights and obligations hereunder in connection
with the transfer or sale of all or substantially all of its business relating
to HMG-1 inhibitors and antagonists (including that certain Sponsored Research
and License Agreement between CTI and NS), or in the event of its merger or
consolidation. Any purported assignment in violation of the preceding sentence
shall be void. Any permitted assignee shall assume all obligations of its
assignor under this License Agreement. NS shall have the right to sell, assign
or otherwise transfer its entire right, title and interest to the patent
applications and/or patents within the NS HMG-1 Patent Rights to an NS
Affiliate, provided the Affiliate assumes all of the obligations of NS
hereunder. Otherwise, NS shall not sell, assign or otherwise transfer title or
any portion thereof to any patent application or patent within the NS HMG-1
Patent Rights as long as exclusive licenses under that patent application and/or
patent are still held by CTI without the prior written consent of CTI, which
consent will not be unreasonably withheld.

      9.3. Severability. Each party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country or
community or association of countries. Should one or more provisions of this
License Agreement be or become invalid, the parties hereto shall substitute, by
mutual consent, valid provisions for such invalid provisions, which valid
provisions in their economic effect are sufficiently similar to the invalid
provisions that it can be reasonably assumed that the parties would have entered
into this License Agreement with such valid provisions. In case such valid
provisions cannot be agreed upon, the invalidity of one or several provisions of
this License Agreement shall not affect the validity of this License Agreement,
as a whole, unless the invalid provisions are of such essential importance to
this License Agreement that it is to be reasonably assumed that the parties
would not have entered into this License Agreement without the invalid
provisions.

                                       9
<PAGE>

      9.4. Notices. Any consent, notice or report required or permitted to be
given or made under this License Agreement by one of the parties hereto to the
other shall be in writing, delivered personally or by facsimile or courier,
postage prepaid (where applicable), addressed to such other party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor, and shall be effective upon receipt by
the addressee.

           If to CTI:  Critical Therapeutics, Inc.
                       c/o HealthCare Ventures LLC
                       One Kendall Square, Building 300, Suite 329
                       Cambridge, Massachusetts 02139

                       Attention: Christopher K. Mirabelli, Ph.D.,
                                    Acting President
                       Fax: (617) 252-4342

           If to NS:   North Shore - Long Island Jewish Research Institute
                       350 Community Drive
                       Manhasset, New York 11030

                       Attention: Chief Executive Officer

      9.5. Applicable Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York.

      9.6. Dispute Resolution. Any disputes arising between the parties relating
to, arising out of or in any way connected with this License Agreement or any
term or condition hereof, or the performance by either party of its obligations
hereunder, whether before or after termination of this License Agreement, shall
be promptly presented to the President of CTI and the Chief Executive Officer of
NS for resolution. If prompt resolution is not reached, the dispute may be
submitted to the American Arbitration Association in New York, New York for
non-binding mediation.

      9.7. Entire Agreement. This License Agreement contains the entire
understanding of the parties with respect to the subject matter hereof. All
express or implied agreements and understandings, either oral or written,
heretofore made are expressly merged in and made a part of this License
Agreement. This License Agreement may be amended, or any term hereof modified,
only by a written instrument duly executed by both parties hereto.

      9.8. Headings. The captions to the several articles hereof are not a part
of this License Agreement, but are merely guides or labels to assist in locating
and reading the several articles.

      9.9. Independent Contractors. It is expressly agreed that CTI and NS are
independent contractors and that the relationship between the two parties shall
not constitute a partnership, joint venture or agency. Neither CTI nor NS shall
have the authority to make any statements, representations or commitments of any
kind, or to take any action, which shall be binding on the other, without the
prior consent of the other party to do so.

                                       10
<PAGE>

      9.10. Waiver. The waiver of either party hereof of any right hereunder or
the failure to perform or of a breach by the other party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.

      9.11. Counterparts. This License Agreement may be executed in two
counterparts, each of which shall be deemed an original, both of which together
shall constitute one and the same instrument.

      9.12. Use of Names. NS and CTI (and its respective Affiliates) each shall
not use the name of the other without prior written consent of the other, which
shall not be unreasonably withheld, except if the use of such name is required
by law, regulation or judicial order, in which event the party intending to use
or using such name will promptly inform the other party of such required use.

      IN WITNESS WHEREOF, the parties have executed this License Agreement as of
the date set forth below.

Critical Therapeutics, Inc.              North Shore - Long Island Jewish
                                         Research Institute

By:/s/H. Shaw Warren                     By:/s/ Nicholas Chiorazzi
   ------------------------------------     ------------------------------------
Its:  Chairman of Board                  Its: Director and CEO
      ---------------------------------       ----------------------------------
Date:7/2/01                              Date: June 29, 2001
     ----------------------------------        ---------------------------------

Agreed to and Accepted as of the Effective Date

By:/s/Kevin J. Tracey
   ------------------------------------
    Kevin J. Tracey, M.D.

                                       11
<PAGE>

                                  SCHEDULE 1.8

                             NS HMG-1 PATENT RIGHTS

<TABLE>
<CAPTION>
COUNTRY            APPLICATION NO.      FILING DATE      INVENTORS      TITLE
-------            ---------------      -----------      ---------      -----
<S>                <C>                  <C>              <C>            <C>
U.S.                     [**]               [**]            [**]         [**]
International            [**]               [**]            [**]         [**]
U.S.                     [**]               [**]            [**]         [**]
U.S.                     [**]               [**]            [**]         [**]
</TABLE>

Note: The U.S. Government may have rights, as specified in Article 2.2, in
Application Numbers [**], [**] and U.S. Provisional Application No. [**].
Additionally, the Provisional Patent Application [**] may be jointly owned by NS
and others.

                                       12
<PAGE>

                            FIRST AMENDMENT AGREEMENT

      This Amendment Agreement is made effective May 15, 2003 by and between
North Shore-Long Island Jewish Research Institute, a New York not-for-profit
corporation having an office and place of business at 350 Community Drive,
Manhasset, NY 11030 ("NS"), and Critical Therapeutics, Inc., a Delaware
corporation having an office and place of business at 675 Massachusetts Avenue,
14th Floor, Cambridge, MA 02139 ("CTI").

                                    STATEMENT

      NS and CTI are parties to a License Agreement having an Effective Date of
July 1, 2001 (the "License Agreement"). NS has entered into an
Inter-Institutional Agreement having an Effective Date of July 1, 2001 (the
"Pittsburgh IIA") with the University of Pittsburgh of the Commonwealth System
of Higher Education ("Pittsburgh") and a separate Inter-Institutional Agreement
having an Effective Date of July 1, 2001 (the "MGH IIA") with The General
Hospital Corporation doing business as The Massachusetts General Hospital
("MGH"), copies of which are attached hereto as Appendix A (the Pittsburgh IIA)
and Appendix B (the MGH IIA), concerning certain "Joint Inventions" and "Joint
Patents" (as consistently defined separately in both the Pittsburgh IIA and the
MGH IIA). NS and CTI wish to make changes to the License Agreement in view of
the rights to Joint Patents and Joint Inventions obtained by NS under the
Pittsburgh IIA and the MGH IIA.

      NOW, THEREFORE, in consideration of the mutual covenants contained in the
License Agreement and in this First Amendment Agreement and other good and
valuable consideration the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:

      1. The following new paragraph is hereby added to Article 2 of the License
Agreement:

<PAGE>

            2.1.1 NS hereby grants to CTI and its Affiliates, on behalf of
                  itself, Pittsburgh and MGH, a royalty-bearing, sole and
                  exclusive license in the Territory, with the right to
                  sublicense, to make, have made, use, offer for sale, sell
                  and/or import Product(s) (as such term is defined in the
                  License Agreement) under Joint Patents and Joint Inventions
                  (as those terms are consistently defined separately in both
                  the Pittsburgh IIA and the MGH IIA), subject to the terms and
                  conditions of, with respect to Pittsburgh, the Pittsburgh IIA
                  and, with respect to MGH, the MGH IIA.

      2. The following new sentence is hereby appended to Section 2.3 of the
License Agreement:

            The Retention of NS Rights in this Article 2.3 of the License
                  Agreement shall further include the reserved rights pursuant
                  to Section 3.2 of the Pittsburgh IIA, attached hereto in its
                  entirety as Appendix A, and to Section 3.2 of the MGH IIA,
                  attached hereto in its entirety as Appendix B.

      3. The following new paragraphs are hereby added to Article 8 of the
License Agreement:

            8.3   INDEMNIFICATION OF MGH. CTI shall indemnify, defend and hold
                  harmless MGH and its trustees, officers, medical and
                  professional staff employees, and agents and their respective
                  successors, heirs and assigns (the "MGH Indemnitees"), against
                  any liability, damage, loss or expense (including reasonable
                  attorney's fees and

                                       2
<PAGE>

                  expenses of litigation) incurred by or imposed upon the MGH
                  Indemnitees or any one of them in connection with any claims,
                  suits, actions, demands or judgments for bodily injury or
                  property damage arising out of any theory of product liability
                  (including, but not limited to, actions in the form of tort,
                  warranty, or strict liability) concerning any product, process
                  or service made, used or sold pursuant to any right or license
                  granted under this First Amendment Agreement.

            8.3.1 CTI's indemnification under Section 8.3 above shall not apply
                  to any liability, damage, loss or expense to the extent that
                  it is directly attributable to the grossly negligent
                  activities or intentional misconduct of the MGH Indemnitees.

            8.3.2 CTI agrees, at its own expense, to provide attorneys
                  reasonably acceptable to the MGH to defend against any actions
                  brought or filed against any party indemnified hereunder with
                  respect to the subject of indemnity contained herein, whether
                  or not such actions are rightfully brought.

            8.3.3 This entire Section 8.3 shall survive expiration or
                  termination of this Agreement.

            8.4   INSURANCE. Beginning at the time any such product, process or
                  service is being commercially distributed or sold (other than
                  for the purpose of obtaining regulatory approvals) by CTI or
                  by a sublicensee, affiliate or agent of CTI, CTI shall, at its
                  sole cost and

                                       3
<PAGE>

                  expense, procure and maintain commercial general liability
                  insurance in amounts not less than $2,000,000 per incident and
                  $3,000,000 annual aggregate and naming the MGH Indemnitees as
                  additional insureds. Such commercial general liability
                  insurance shall provide (i) product liability coverage and
                  (ii) contractual liability coverage for CTI's indemnification
                  under this First Amendment Agreement. If CTI elects to
                  self-insure all or part of the limits described above
                  (including deductibles or retentions which are in excess of
                  $250,000 annual aggregate) such self-insurance program must be
                  acceptable to the MGH and the Risk Management Foundation of
                  the Harvard Medical Institutions, Inc. The minimum amount of
                  insurance coverage required hereunder shall not be construed
                  to create a limit of CTI's liability with respect to its
                  indemnification obligations under this First Amendment
                  Agreement.

            8.4.1 CTI shall provide MGH with written evidence of such insurance
                  upon request of MGH. CTI shall provide MGH with written notice
                  at least fifteen (15) days prior to the cancellation or
                  non-renewal in such insurance; if CTI does not obtain
                  replacement insurance providing comparable coverage within
                  such fifteen (15) day period, MGH shall have the right to
                  terminate this First Amendment Agreement effective at the end
                  of such fifteen (15) day period without notice or any
                  additional waiting periods.

                                       4
<PAGE>

            8.4.2 CTI shall maintain such commercial general liability insurance
                  during (i) the period that any such product, process or
                  service is being commercially distributed or sold (other than
                  for the purpose of obtaining regulatory approvals) by CTI or
                  by a sublicensee, affiliate or agent of CTI and (ii) a
                  reasonable period after the period referred to in (c)(i) above
                  which in no event shall be less than fifteen (15) years.

            8.4.3 This entire Section 8.4 shall survive expiration or
                  termination of this Agreement.

            8.5   INDEMNIFICATION OF PITTSBURGH. CTI shall indemnify, defend and
                  hold harmless Pittsburgh and its trustees, officers, medical
                  and professional staff employees, and agents and their
                  respective successors, heirs and assigns (the "Pittsburgh
                  Indemnitees"), against any liability, damage, loss or expense
                  (including reasonable attorney's fees and expenses of
                  litigation) incurred by or imposed upon the Pittsburgh
                  Indemnitees or any one of them in connection with any claims,
                  suits, actions, demands or judgments for bodily injury or
                  property damage arising out of any theory of product liability
                  (including, but not limited to, actions in the form of tort,
                  warranty, or strict liability) concerning any product, process
                  or service made, used or sold pursuant to any right or license
                  granted under this First Amendment Agreement.

                                       5
<PAGE>

            8.5.1 CTI's indemnification under Section 8.5 above shall not apply
                  to any liability, damage, loss or expense to the extent that
                  it is directly attributable to the grossly negligent
                  activities or intentional misconduct of the Pittsburgh
                  Indemnitees.

            8.5.2 CTI agrees, at its own expense, to provide attorneys
                  reasonably acceptable to the Pittsburgh to defend against any
                  actions brought or filed against any party indemnified
                  hereunder with respect to the subject of indemnity contained
                  herein, whether or not such actions are rightfully brought.

            8.5.3 This entire Section 8.5 shall survive expiration or
                  termination of the License Agreement.

            8.6   INSURANCE. Beginning at the time any such product, process or
                  service is being commercially distributed or sold (other than
                  for the purpose of obtaining regulatory approvals) by CTI or
                  by a sublicensee, affiliate or agent of CTI, CTI shall, at its
                  sole cost and expense, procure and maintain commercial general
                  liability insurance in amounts not less than $2,000,000 per
                  incident and $3,000,000 annual aggregate and naming the
                  Pittsburgh Indemnitees as additional insureds. Such commercial
                  general liability insurance shall provide (i) product
                  liability coverage and (ii) contractual liability coverage for
                  CTI's indemnification under this First Amendment Agreement. If
                  CTI elects to self-insure all or part of the limits described
                  above (including deductibles or

                                       6
<PAGE>

                  retentions which are in excess of $250,000 annual aggregate)
                  such self-insurance program must be acceptable to Pittsburgh.
                  The minimum amount of insurance coverage required hereunder
                  shall not be construed to create a limit of CTI's liability
                  with respect to its indemnification obligations under this
                  First Amendment Agreement.

            8.6.1 CTI shall provide Pittsburgh with written evidence of such
                  insurance upon request of Pittsburgh. CTI shall provide
                  Pittsburgh with written notice at least fifteen (15) days
                  prior to the cancellation or non-renewal in such insurance; if
                  CTI does not obtain replacement insurance providing comparable
                  coverage within such fifteen (15) day period, Pittsburgh shall
                  have the right to terminate this First Amendment Agreement
                  effective at the end of such fifteen (15) day period without
                  notice or any additional waiting periods.

            8.6.2 CTI shall maintain such commercial general liability insurance
                  during (i) the period that any such product, process or
                  service is being commercially distributed or sold (other than
                  for the purpose of obtaining regulatory approvals) by CTI or
                  by a sublicensee, affiliate or agent of CTI and (ii) a
                  reasonable period after the period referred to in (c)(i) above
                  which in no event shall be less than fifteen (15) years.

                                       7
<PAGE>

            8.6.3 This entire Section 8.6 shall survive expiration or
                  termination of the License Agreement.

      4. Within sixty (60) days of the execution of this First Amendment
Agreement, CTI shall pay to NS Five Thousand Dollars ($5,000) pursuant to
paragraph 4.2(b) of the License Agreement.

      5. The applicable provisions of this First Amendment Agreement shall be
deemed to be incorporated into the License Agreement in full and to be an
integral part thereof as though fully set forth therein. With the exception of
the above amendments, all other provisions of the License Agreement shall remain
in full force and effect.

      IN WITNESS WHEREOF, the parties hereto have entered into and executed this
First Amendment Agreement on the date first above written.

NORTH SHORE - LONG ISLAND JEWISH         CRITICAL THERAPEUTICS, INC.
RESEARCH INSTITUTE

By: /s/ Robin D. Wittenstein             By: /s/ Paul D. Rubin
   ------------------------------------      -----------------------------------

Name:  Robin D. Wittenstein              Name:  Paul D. Rubin

Title:  Vice President and COO           Title:  CEO and President

AGREED TO AND ACCEPTED BY:               AGREED TO AND ACCEPTED BY:

THE MASSACHUSETTS GENERAL HOSPITAL       UNIVERSITY OF PITTSBURGH OF THE
("MGH")                                  COMMONWEALTH SYSTEM OF HIGHER EDUCATION
                                         ("PITTSBURGH")

Name: /s/ Frances Tomeguzzo, Ph.D.       Name: /s/ Jerome Cochran
     ----------------------------------        ---------------------------------

Title:  Director, Corporate Sponsored    Title:  Executive Vice Chancellor
Research and Licensing

Date:  7/2/03                            Date:  7/2/03

                                       8<PAGE>

          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.

                                                                    Exhibit 10.6

                    SPONSORED RESEARCH AND LICENSE AGREEMENT

                                     BETWEEN

                           CRITICAL THERAPEUTICS, INC.

                                       AND

               NORTH SHORE - LONG ISLAND JEWISH RESEARCH INSTITUTE
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<S>                                                                               <C>
ARTICLE 1. DEFINITIONS..........................................................   1

         1.1.     "Affiliate"...................................................   1
         1.2.     "Effective Date"..............................................   2
         1.3.     "Field".......................................................   2
         1.4.     "First Commercial Sale".......................................   2
         1.5.     "License Term"................................................   2
         1.6.     "Net Sales"...................................................   2
         1.7.     "NS Know-How".................................................   2
         1.8.     "NS Valid Patent Claim".......................................   2
         1.9.     "Other NS Technology".........................................   3
         1.10.    "Product(s)"..................................................   3
         1.11.    "Research Plan"...............................................   3
         1.12.    "Research Steering Committee".................................   3
         1.13.    "Research Term"...............................................   3
         1.14.    "Research Year"...............................................   3
         1.15.    "Sponsored Technology"........................................   3
         1.16.    "Territory"...................................................   4

ARTICLE 2. SPONSORED RESEARCH...................................................   4

         2.1.     CTI Support...................................................   4
         2.2.     Research Steering Committee...................................   4
         2.3.     Conduct of the Sponsored Research.............................   5
         2.4.     Visit of Facilities...........................................   6

ARTICLE 3. LICENSE AND OPTION GRANTS............................................   6

         3.1.     License Grant.................................................   6
         3.2.     Option Grant..................................................   7
         3.3.     Retention of NS Rights........................................   7

ARTICLE 4. LICENSE CONSIDERATION, MILESTONES AND ROYALTIES......................   8

         4.1.     Issuance of Shares............................................   8
         4.2.     Vesting of Shares.............................................   9
         4.3.     Cash Payments.................................................   9
         4.4.     Royalties.....................................................  10
         4.5.     Sublicense Income.............................................  11
         4.6.     Milestone and Royalty Limitations.............................  11
ARTICLE 5. PATENTS..............................................................  12

         5.1.     CTI Authority.................................................  12
         5.2.     Patent Expenses...............................................  12
         5.3.     Right of NS to be Informed....................................  12
         5.4.     NS Rights.....................................................  12
         5.5.     Enforcement of NS Patent Rights...............................  13
</TABLE>

                                       i
<PAGE>
<TABLE>
<S>                                                                               <C>
ARTICLE 6. CONFIDENTIALITY AND PUBLICATION......................................  13

         6.1.     Non-Disclosure Obligations....................................  13
         6.2.     Release of Obligations........................................  13
         6.3.     Publications..................................................  14

ARTICLE 7. REPRESENTATIONS AND WARRANTIES.......................................  14

         7.1.     Authorization.................................................  14
         7.2.     License Warranty..............................................  14
         7.3.     Remedies......................................................  14
         7.4.     Further Representations of CTI................................  14
         7.5.     Further Representations of NS.................................  15

ARTICLE 8. TERM AND TERMINATION.................................................  16

         8.1.     Expiration....................................................  16
         8.2.     Termination for Cause.........................................  16
         8.3.     Effect of Termination.........................................  16

ARTICLE 9. INDEMNIFICATION AND INSURANCE........................................  16

         9.1.     Indemnity.....................................................  16
         9.2.     Insurance.....................................................  17

ARTICLE 10. MISCELLANEOUS.......................................................  17

         10.1.    Force Majeure.................................................  17
         10.2.    Assignment....................................................  17
         10.3.    Severability..................................................  18
         10.4.    Notices.......................................................  18
         10.5.    Applicable Law................................................  18
         10.6.    Dispute Resolution............................................  19
         10.7.    Entire Agreement..............................................  19
         10.8.    Headings......................................................  19
         10.9.    Independent Contractors.......................................  19
         10.10.   Waiver........................................................  19
         10.11.   Counterparts..................................................  19
         10.12.   Use of Names..................................................  20
</TABLE>

                                       ii
<PAGE>
                    SPONSORED RESEARCH AND LICENSE AGREEMENT

         This Sponsored Research and License Agreement (the "Research
Agreement") is made between Critical Therapeutics, Inc. (formerly known as
Medicept, Inc.), a Delaware corporation ("CTI") and North Shore - Long Island
Jewish Research Institute, a New York non-profit corporation ("NS").

                                    RECITALS

         WHEREAS, CTI and NS desire to identify inhibitors and/or antagonists of
High Mobility Group 1 Protein (HMG-1) and related proteins, including antibodies
and fragments thereof, inhibitors and antagonists thereof; and

         WHEREAS, NS desires to receive research support from CTI relating to
identifying such inhibitors and/or antagonists and to have CTI develop and
commercialize products resulting from such research;

         WHEREAS, CTI is willing to sponsor such research at NS on the terms set
forth herein; and

         WHEREAS, CTI desires to be licensed under such Sponsored Research and
related technology of NS and NS is willing to license CTI on the terms set forth
herein;

         NOW, THEREFORE, in consideration of the premises and of the covenants
herein contained, CTI and NS mutually agree as follows:

                             ARTICLE 1. DEFINITIONS

         For purposes of this Research Agreement, the terms defined in this
Article shall have the meanings specified below:

         1.1. "Affiliate" shall mean any corporation or other entity which
controls, is controlled by, or is under common control with a party to this
Research Agreement. A corporation or other entity shall be regarded as in
control of another corporation or entity if it owns or directly or indirectly
controls more than fifty percent (50%) of the voting stock or other ownership
interest of the other corporation or entity, or if it possesses, directly or
indirectly, the power to direct or

                                       1
<PAGE>
cause the direction of the management and policies of the corporation or other
entity or the power to elect or appoint fifty percent (50%) or more of the
members of the governing body of the corporation or other entity.

         1.2. "Effective Date" of this Research Agreement shall mean July 1,
2001.

         1.3. "Field" shall mean the therapeutic, prophylactic and/or diagnostic
use of inhibitors and/or antagonists of HMG-1 and related proteins (that is,
proteins that contain the HMG boxes), including, but not limited to, antibodies
and fragments thereof, inhibitors and antagonists thereof.

         1.4. "First Commercial Sale" of any Product shall mean the first sale
for use or consumption by the general public of such Product in a country.

         1.5. "License Term" shall mean the later of ten years from the First
Commercial Sale for each Product or the last to expire of the NS Patent Rights
covering each Product on a country-by-country basis.

         1.6. "Net Sales" shall mean the gross amount billed or invoiced and
received by CTI or its Affiliates (but not sublicensees) for sale or other
disposition of Product(s) to independent third parties, less the following: (i)
customary trade, quantity, or cash discounts to the extent actually allowed and
taken; (ii) amounts repaid and credited by reason of rejection or return; and
(iii) to the extent separately stated on purchase orders, invoices, or other
documents of sale, any taxes or other governmental charges levied on the
production, sale, transportation, delivery, or use of the Product that is paid
by or on behalf of CTI or its Affiliates. Net Sales will be determined from the
books and records of CTI and its Affiliates maintained in accordance with
generally accepted accounting principles, consistently applied.

         1.7. "NS Know-How" shall mean all Sponsored Technology which is not
covered by an NS Valid Patent Claim.

         1.8. "NS Valid Patent Claim" shall mean either (a) a claim of an issued
and unexpired patent included within the NS Patent Rights, which has not been
held permanently revoked, unenforceable or invalid by a decision of a court or
other governmental agency of competent

                                       2
<PAGE>
jurisdiction, unappealable or unappealed within the time allowed for appeal, and
which has not been admitted to be invalid or unenforceable through reissue,
disclaimer or otherwise or (b) a claim of any pending patent application
included within the NS Patent Rights, which claim was filed in good faith and
has not been abandoned or finally disallowed without the possibility of appeal
or refiling of said application.

         1.9. "Other NS Technology" shall mean any invention not included in
Sponsored Technology and which relates to the Field that is invented or
co-invented by Kevin T. Tracey, Ph.D., and/or any other employee(s) of NS under
the direct supervision of Dr. Tracey and is owned or controlled by NS on the
Effective Date of this Research Agreement or subsequently becomes owned or
controlled by NS during the Research Term.

         1.10. "Product(s)" shall mean any product or service in the Field: (1)
covered by an NS Valid Patent Claim; (2) made by a process covered by an NS
Valid Patent Claim; or (3) the manufacture, use, practice or sale of which
involves the use of Sponsored Technology.

         1.11. "Research Plan" shall mean the research program described in
Attachment A hereto, as revised from time to time as provided for in this
Research Agreement.

         1.12. "Research Steering Committee" shall mean the joint committee
composed of representatives of CTI and NS described in Article 2.2 of this
Research Agreement.

         1.13. "Research Term" shall mean the two-year period starting on the
first day of the month following the Effective Date of this Research Agreement
and any extension of this period mutually agreed upon by CTI and NS.

         1.14. "Research Year" shall mean each twelve-month period of the
Research Term with the first Research Year beginning on the first day of the
month following the Effective Date of this Research Agreement.

         1.15. "Sponsored Technology" shall mean all information, data,
know-how, materials (including biological materials), inventions (whether
patentable or not), software, models, screens, trade secrets, patents, patent
applications and other intellectual property of any kind, whether patented or
unpatented, in the Field, owned or controlled by NS during the term of this

                                       3
<PAGE>
Research Agreement and conceived, made, developed or acquired pursuant to the
Research Plan. Sponsored Technology shall include, without limitation, (1) all
patents and patent applications claiming any part of the Sponsored Technology
and any continuations, continuations-in-part, divisionals, reissues, renewals,
reexaminations, substitutions or extensions thereof, and any foreign
counterparts thereof owned or controlled by NS (the "NS Patent Rights"), (2) all
trade secrets, know-how and rights owned or controlled by NS and relating to
Sponsored Technology, including any enhancements, updates, extensions and
improvements thereof, and (3) all competitive assessments and market analyses by
or for NS of related technology and intellectual property of third parties.
Notwithstanding the foregoing, continuation-in-part applications licensed to CTI
under that certain License Agreement between NS and CTI shall be excluded from
Sponsored Technology under this Research Agreement.

         1.16. "Territory" shall mean the entire world.

                         ARTICLE 2. SPONSORED RESEARCH

         2.1. CTI Support. CTI agrees to financially support research at NS in
the Field for the Research Term. The amount of CTI financial support shall be:

<TABLE>
<S>                                                 <C>
              First Research Year                   Two Hundred Thousand Dollars
                                                    ($200,000.00)

              Second Research Year                  Two Hundred Thousand Dollars
                                                    ($200,000.00)

              Subsequent Research Year(s)           To be mutually agreed upon.
</TABLE>

CTI shall make payments of Fifty Thousand Dollars ($50,000.00) to NS in advance
of the commencement of the Research Term and in advance of each three-month
anniversary thereof.

         2.2. Research Steering Committee. A joint committee comprised of two
(2) named representatives of CTI and NS (the "Research Steering Committee")
shall be appointed on or before the Effective Date and shall meet once each
calendar quarter during the Research Term. Meetings shall be held within thirty
(30) days of the end of the preceding calendar quarter. Such meetings shall be
at times and places agreed upon, or in such other form (e.g., telephone or video

                                       4
<PAGE>
conference) as the members of the Research Steering Committee shall agree. At
such meetings, the principal function of the Research Steering Committee shall
be to discuss progress or lack thereof under the Research Plan, set future
priorities thereunder, consider and make any necessary or desirable amendments
to the Research Plan and determine whether any particular HMG-1 modulators
should be recommended to CTI for consideration for development into Products.
Members of the Research Steering Committee may be represented at any meeting by
another member of the Research Steering Committee, or by a deputy. Any approval,
determination or other action agreed to by all of the members of the Research
Steering Committee or their deputies present at the relevant Research Steering
Committee meeting shall be the approval, determination or other action of the
Research Steering Committee, provided that at least two representatives of each
party are present at such meeting.

         2.3. Conduct of the Sponsored Research. The conduct of the Sponsored
Research shall be the primary responsibility of NS according to the Research
Plan, with participation, as appropriate, by CTI. The Sponsored Research shall
be conducted in good scientific manner, and in compliance with all applicable
good laboratory practices, and applicable legal requirements, to attempt to
achieve efficiently and expeditiously the objectives described in the Research
Plan. NS shall proceed diligently with the work set out in the Research Plan
using efforts consistent with NS's best research practices. Without limiting the
generality of the foregoing:

            2.3.1. Use of Research Funding. NS shall apply the research funding
it receives from CTI under this Research Agreement to conduct the research set
forth in the Research Plan.

            2.3.2. Other Funding. During the Research Term, NS shall not accept
research funding from any third-party, including the U.S. Government, except for
funding from the National Institutes of Health, for any of the work described in
the Research Plan without prior written approval from CTI, such approval not to
be unreasonably withheld.

            2.3.3. Data. NS shall maintain records in sufficient detail and in
good scientific manner as will properly reflect all work done and results
achieved in the performance of the Research Plan (including all data in the form
required to be maintained under applicable governmental regulations). Such
records shall include books, records, reports, research notes, charts, graphs,
comments, computations, analyses, recordings, photographs, computer programs

                                       5
<PAGE>
and documentation thereof, computer information storage means, samples of
materials and other graphic or written data generated in connection with the
Research Plan. NS shall provide CTI with the right to inspect such records, and
shall provide copies of all requested records, to the extent reasonably required
by CTI. Further, NS will instruct all of its employees doing Sponsored Research
to record their inventions in bound laboratory notebooks and to sign and date
each notebook page and have it read, witnessed and signed by a scientific
colleague who is not a co-inventor of the work described.

            2.3.4. Quarterly Reports. Within fourteen (14) days following the
end of each calendar quarter, NS shall provide to the Research Steering
Committee written reports which summarize in reasonable detail the work it has
performed under the Research Plan during the preceding calendar quarter.

            2.3.5. Research Steering Committee Quarterly Reports. Within
fourteen (14) days following each regular meeting of the Research Steering
Committee held pursuant to the provisions of Section 2.2 hereof, the Research
Steering Committee shall prepare and send to CTI a reasonably detailed written
report which shall (a) comment on the reports received under Section 2.3.4 and
forwarded to CTI with such comments and provide recommendations with respect to
future research directions, (b) state any determination of the Research Steering
Committee to recommend inhibitors and/or antagonists of HMG-1 or related
proteins for further development by CTI and (c) state any determination of the
Research Steering Committee to not proceed with further research or development
of an inhibitor and/or antagonist and the reasons therefor.

         2.4. Visit of Facilities. Representatives of CTI may, upon reasonable
notice and at times reasonably acceptable to NS, (a) visit the NS facilities
where the Sponsored Research is being conducted, and (b) consult informally,
during such visits, and by telephone at other times, with personnel of NS
performing the Sponsored Research.

                      ARTICLE 3. LICENSE AND OPTION GRANTS

         3.1. License Grant. NS hereby grants to CTI and its Affiliates a
royalty-bearing, sole and exclusive license in the Territory, with the right to
sublicense, to make, have made, use, offer for sale, sell and/or import
Product(s) under Sponsored Technology. CTI shall provide NS with

                                       6
<PAGE>
a full and complete copy of any sublicense granted pursuant to this Research
Agreement and any documents evidencing the consideration to be paid to CTI or
its Affiliates relating to the grant of any such sublicense within thirty (30)
days of execution thereof by CTI. CTI acknowledges and agrees that its exclusive
license under any patent application and/or patent licensed hereunder is subject
to the rights of any joint owners of such patent application and/or patent.

         3.2. Option Grant. NS additionally grants to CTI a first and sole
option to acquire one or more licenses to Other NS Technology. NS shall promptly
give notice to CTI of any invention included in Other NS Technology. Following
such notice, at the option of CTI, CTI and NS shall enter into good-faith
negotiations regarding the granting of a sole and exclusive license from NS to
CTI of such Other NS Technology, to the extent that NS has the legal right to do
so, such license to be granted upon mutually agreeable terms and conditions
which are reasonable under the circumstances. If CTI and NS are unable to agree
upon the terms of any such license, NS agrees not to grant any license during
the Research Term to a third-party to such Other NS Technology upon different
terms without having first offered such different terms to CTI. CTI shall have
sixty (60) days in which to determine whether or not such terms are acceptable
to it. If CTI fails to notify NS in writing within such sixty (60) days that CTI
accepts such terms, CTI shall be deemed to have rejected such offer, and NS
shall be free thereafter to enter into any such license or other disposition of
such Other NS Technology for such purposes that it may wish to make to other
parties on financial terms no more favorable to the other party or parties than
those so rejected by CTI. If CTI notifies NS in writing within such sixty (60)
days that CTI accepts the terms offered by NS, CTI shall be deemed to have
entered into a binding license agreement with NS on terms and conditions offered
by NS, and the parties shall thereafter promptly execute and deliver a separate
confirmatory license agreement incorporating all such terms and any other terms
and conditions in addition thereto, and not in conflict therewith, on which the
parties may agree.

         3.3. Retention of NS Rights. Notwithstanding the exclusive rights
granted to CTI pursuant to Article 3.1, NS shall retain the right to make and
use Products in its own laboratories solely for non-commercial, scientific
purposes and for continued non-commercial research.

                                       7
<PAGE>
           ARTICLE 4. LICENSE CONSIDERATION, MILESTONES AND ROYALTIES

         4.1. Issuance of Shares.

            4.1.1. Within sixty (60) days after the Effective Date, CTI shall
issue and deliver to NS twenty-thousand (20,000) shares of CTI restricted,
pre-split Common Stock. Five thousand (5,000) of such shares shall initially be
vested, and the remaining fifteen thousand (15,000) shares shall initially be
unvested but subject to vesting during the term of this Agreement as provided in
Section 4.2. The share numbers referred to in Articles 4.1 and 4.2 are based on
the capitalization of CTI prior to the stock split referred to in Section 7.4.2
which is contemplated to occur around the Effective Date of this Research
Agreement. Upon such stock split such share numbers will be appropriately
adjusted.

            4.1.2. NS may not sell, assign, transfer, pledge, or grant a
security interest in any unvested shares other than to an NS Affiliate; provided
that it shall be a condition of any transfer of shares to an Affiliate that the
transferee agree in writing with CTI to take such shares subject to the
applicable restrictions of this Research Agreement.

            4.1.3. In the event that NS terminates this Research Agreement under
Section 8.2 due to material breach hereof by CTI, all then-unvested shares
(except the 5,000 shares described in Section 4.2.1, if then-unvested) shall
immediately become vested. In the event this Research Agreement and the License
Agreement between CTI and NS both terminate for any other reason prior to all
shares becoming vested, all then-unvested shares shall thereupon be forfeited
and redeemed for no consideration payable to NS and NS shall return the
certificate representing such unvested shares to CTI for cancellation.

            4.1.4. If after the Effective Date or the execution of this Research
Agreement (as the case may be), and prior to the issuance and delivery of shares
under Section 4.1.1, as a result of a merger, consolidation, sale of all or
substantially all of the assets of CTI, reorganization, recapitalization,
reclassification, stock dividend, stock split, reverse stock split or other
distribution with respect to the outstanding shares of Common Stock or other
securities, the outstanding shares of Common Stock are increased or decreased,
or are exchanged for a different number or kind of shares or other securities,
or if additional shares or new or different shares of other securities are
distributed with respect to such shares of Common Stock or other securities,

                                       8
<PAGE>
an appropriate and proportionate adjustment may be made in the number and kind
of shares or other securities to be delivered to and vested in NS pursuant to
Articles 4.1 and 4.2.

            4.1.5. All unvested shares (except the 5,000 shares described in
Section 4.2.1, if then-unvested) shall become vested shares immediately upon any
liquidation, dissolution or sale of CTI (including without limitation any sale
of all or substantially all the assets of CTI and any merger or consolidation as
a result of which the holders of CTI' s equity securities immediately prior to
such merger or consolidation cease to hold at least a majority of the voting
securities of the successor entity); provided, however, that such acceleration
shall not occur if this Research Agreement and the License Agreement referred to
in Article 4.1.3 are assumed by the acquiring or surviving entity without
diminution of benefits to NS.

         4.2. Vesting of Shares. The initially-unvested shares issued under
Section 4.1.1 shall vest as follows, provided in each case that this Research
Agreement has not then been terminated:

            4.2.1. Five-thousand (5,000) shares shall vest at such time as NS
provides the Company with copies of documents evidencing that NS is rightfully
designated as the only Applicant on Patent Cooperation Treaty Application Number
[**] or other evidence that NS is the sole owner of the foreign patent rights
for inventions described in U.S. Applications Serial Numbers [**] and [**], as
provided in that certain License Agreement between CTI and NS.

            4.2.2. Five thousand (5,000) shares shall vest on the fifth (5th)
anniversary of the Effective Date.

            4.2.3. Five thousand (5,000) shares shall vest on the sixth (6th)
anniversary of the Effective Date.

         4.3. Cash Payments. Upon achieving the milestones specified herein, CTI
shall pay to NS the following cash payments:

            (a) for Products covered by an NS Valid Patent Claim or made by a
process covered by an NS Valid Patent Claim:

                                       9
<PAGE>
                (i) [**] Dollars ($[**]) upon [**] for the [**] covered by an NS
Valid Patent Claim; and

                (ii) [**] Dollars ($[**]) upon [**]covered by an NS Valid Patent
Claim;

            (b) for Products not covered by an NS Valid Patent Claim:

                (i) [**] Dollars ($[**]) upon [**]; and,

                (ii) [**] Dollars ($[**]) upon [**].

         4.4. Royalties. CTI shall additionally pay to NS royalties in the
following amounts:

            (a) [**] percent ([**]%) of Net Sales by CTI or its Affiliates for
Products covered by an NS Valid Patent Claim or made by a process covered by an
NS Valid Patent Claim; or

            (b) [**] percent ([**] %) of Net Sales by CTI or its Affiliates for
Products not covered by an NS Valid Patent Claim.

            4.4.1. Royalty Reports and Payments. During the License Term and
following the First Commercial Sale of a Product in each country in the
Territory, CTI and its Affiliates shall furnish to NS quarterly reports within
sixty (60) days of the end of each calendar quarter, showing, on a
country-by-country basis, the gross sales of all Products sold by CTI and its
Affiliates during the reporting period, the calculation of Net Sales from such
gross sales, all consideration received by CTI and/or its Affiliates from
sub-licensees in connection with the grant of any sub-licenses pursuant to this
Agreement and the amount of any payments due to NS. Such quarterly reports shall
be accompanied by payment of the royalty amount or other payments due for that
calendar quarter. CTI and/or its Affiliates shall maintain complete and accurate
books of account and records showing Net Sales and amounts received from
sub-licensees. Such books and records shall be open to inspection, in
confidence, by NS during usual business hours, by an independent certified
public accountant to whom CTI has no reasonable objection, for two (2) years
after the calendar year to which they pertain, for the purpose of verifying the
accuracy of the payments made to NS pursuant to this Agreement. CTI and/or its

                                       10
<PAGE>
Affiliates shall use commercially reasonable efforts to require any
sub-licensees hereunder to maintain such books and allow such inspection by NS
and shall, on request, disclose such information to NS as part of such
inspection. Inspection shall be at NS's sole expense, shall be reasonably
limited to those matters related to the payment obligations under this
Agreement, and shall be permitted no more than once per calendar year.

            4.4.2. One Royalty. Royalty payments pursuant to Article 4.4 shall
be due only on the first sale or other disposition of Product(s) to an
independent third party.

            4.4.3. Incorporation of Other Products. In the event that a Product
is marketed as part of a bundle, system or kit that incorporates or includes
other products, Net Sales will be computed using the average net selling price
of the components when sold separately. If any Product is sold only as part of a
bundle, system or kit and is not sold separately, then Net Sales will include
only that part of such sale reasonably allocable to the Product. In making such
allocation, primary consideration will be given to the added value provided by
the Product as compared to the value of the bundle, system or kit if sold
without it.

            4.4.4. Third-Party Licenses. In the event that CTI or its Affiliates
licenses one or more technologies from third-parries in order to develop and
market Product(s), the amount of royalty payments due to NS under Article 4.4
shall be reduced by an amount equal to [**] percent ([**]%) of the payments due
to third-parties; provided, that in no event shall the royalty payments due to
NS hereunder pursuant to Article 4.4(a) be reduced below [**] percent ([**]%) of
Net Sales by CTI or its Affiliates, or, [**] percent ([**]%) in the case of
royalties due under Article 4.4(b). This paragraph will not apply to any patents
or patent applications issuing from U.S.S.N. [**].

         4.5. Sublicense Income. In the event that CTI or its Affiliates grants
one or more sublicenses under Sponsored Technology, CTI shall pay or cause its
Affiliates to pay, as the case may be, to NS an amount equal to [**] percent
([**]%) of all consideration in any form received by CTI and/or its Affiliates
for the sublicense(s).

         4.6. Milestone and Royalty Limitations. Despite any provision to the
contrary, CTI and its Affiliates shall not be liable under this Research
Agreement for any cash milestone

                                       11
<PAGE>
payments or royalty payments for any product for which milestone and/or royalty
payments are due under that certain License Agreement between CTI and NS.

                               ARTICLE 5. PATENTS

         5.1. CTI Authority. CTI shall have primary responsibility for filing,
prosecuting, issuing, maintaining and defending patent applications and patents
claiming Sponsored Technology in the United States and worldwide, employing
patent counsel of its choice. Initially, CTI's choice for patent counsel is the
firm of Hamilton, Brook, Smith & Reynolds, P.C., Lexington, Massachusetts, for
which NS grants its approval. If CTI decides to retain a different or additional
patent counsel in the future, NS shall have the right to approve CTI's selection
of a different or additional patent counsel, such approval not to be
unreasonably withheld. Patent counsel selected by CTI shall treat NS as its
client and the owner of patents and patent applications claiming Sponsored
Research invented by NS employees.

         5.2. Patent Expenses. CTI agrees to bear the cost for all patent work
performed pursuant to Article 5.1. Bills for such work may be rendered to NS, in
which case CTI agrees to promptly reimburse NS for its expenses in this regard.
Alternatively, for convenience, bills for work performed pursuant to Article 5.1
may be sent directly to CTI for payment, with a copy to NS.

         5.3. Right of NS to be Informed. For work performed by patent counsel
selected by CTI pursuant to Article 5.1, such patent counsel shall keep NS
apprised of the status of each of the patent applications and patents in the NS
Patent Rights and will consult with NS concerning the prosecution of such patent
applications. Such patent counsel will provide NS in a timely manner with copies
of all documents related to the filing, prosecution, issuance, maintenance
and/or defense of such applications or patents in the NS Patent Rights.

         5.4. NS Rights. If CTI decides to abandon any application for a patent
claiming Sponsored Technology or declines to file and prosecute a patent
application which could claim Sponsored Technology and which NS desires to have
filed and prosecuted, it agrees to provide NS with sufficient notice to allow NS
to assume filing and/or prosecution of that application. If NS does assume
prosecution of such application, CTI shall no longer be licensed under that
patent application.

                                       12
<PAGE>
         5.5. Enforcement of NS Patent Rights. If CTI or NS becomes aware of any
actual or potential infringement of NS Patent Rights, it will notify the other
party and CTI and NS will subsequently confer and agree about appropriate action
against such actual or potential infringement. If it is decided to enforce NS
Patent Rights against such infringement, CTI shall have the first right to do so
and NS shall provide full cooperation at the expense of CTI. Any settlement or
recovery received from any such proceeding shall be divided [**] percent ([**]%)
to CTI and [**] percent ([**]%) to NS after CTI deducts from any such settlement
or recovery its reasonable counsel fees and out-of-pocket expenses relative to
any such legal proceeding. If CTI decides not to initiate legal proceedings
against any such infringer, then NS shall have the right to initiate such legal
proceedings. Any settlement or recovery received from any such proceeding shall
be divided [**] percent ([**]%) to NS and [**] percent ([**]%) to CTI after NS
deducts from any such settlement or recovery its reasonable counsel fees and
out-of-pocket expenses relative to any such legal proceeding.

                   ARTICLE 6. CONFIDENTIALITY AND PUBLICATION

         6.1. Non-Disclosure Obligations. During the Research Term and for a
period of ten (10) years thereafter, both parties shall maintain in confidence,
and use only for purposes of this Research Agreement, confidential information
and data received from the other party. Upon expiration or termination of this
Research Agreement, all confidential information and data, and copies thereof
will be returned to the transmitting party by the receiving party upon request
of the transmitting party.

         6.2. Release of Obligations. The obligations under Artic1e 6.1 shall
not apply to any information or data that:

            (a) is or becomes publicly available;

            (b) is disclosed to the receiving party by a third party that is not
under an obligation to other party to this Research Agreement;

            (c) prior to disclosure to the other party, the receiving party was
already in possession of the information or data; or,

                                       13
<PAGE>
            (d) was independently developed by the receiving party without
breach of the obligations of Article 6.1.

         6.3. Publications. NS shall not publish any information generated in
Sponsored Research without prior written approval from CTI after such
information has been submitted to CTI at least thirty (30) days prior to the
intended date of submission for publication. CTI shall not unreasonably withhold
approval of such publication but does have the right to request delay of the
submission for a maximum period of forty-five (45) days to allow for patent
applications covering such information or data to be filed. Nothing herein
contained shall preclude NS from making required reports or disclosures to the
National Institutes of Health.

                   ARTICLE 7. REPRESENTATIONS AND WARRANTIES

         7.1. Authorization. Each party warrants and represents to the other
that it has the legal right and power to enter into this Research Agreement, to
fully perform its obligations hereunder, and that it has not made nor will it
make any commitments to others in conflict with or in derogation of such rights
or this Research Agreement. Except as otherwise disclosed, each party further
represents to the other that it is not aware of any legal obstacles, including
patent rights of others, which could prevent it from carrying out the provisions
of this Research Agreement.

         7.2. License Warranty. In addition, NS warrants and represents that it
has the legal right and power to grant the licenses granted to CTI under this
Research Agreement.

         7.3. Remedies. The liability of NS for CTI's damages for any breach of
the warranties and representations contained in this Article will be limited to
reimbursement to CTI by NS of the total of all of the payments received by NS
pursuant to this Research Agreement.

         7.4. Further Representations of CTI. CTI hereby additionally represents
and warrants as follows:

            7.4.1. Organization and Standing. CTI is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware and has full corporate power and authority to conduct its business as
presently conducted and as proposed to be conducted by it and to enter into and
perform this Agreement and to carry out the transactions

                                       14
<PAGE>
contemplated by this Agreement. CTI is duly qualified to do business as a
foreign corporation and is in good standing in the Commonwealth of Massachusetts
and in every other jurisdiction in which the failure to so qualify would have a
material adverse effect on the operations or financial condition of CTI.

            7.4.2. Capitalization. Post the 5.11111 to 1 split planned for
around the Effective Date of this Research Agreement, the authorized capital
stock of CTI will consist of 18,850,000 shares of common stock, $0.001 par value
per share (the "Common Stock"), of which 4,599,999 shares will be issued and
outstanding, and 10,150,000 shares of Preferred Stock, $.001 par value per
share, of which no shares will be issued and outstanding. All of the issued and
outstanding shares of Common Stock will be duly authorized and validly issued
and will be fully paid and non-assessable. All of the issued and outstanding
shares of Common Stock have been offered, issued and sold by CTI in compliance
with applicable Federal and state securities laws.

            7.4.3. Subsidiaries. CTI has no subsidiaries and does not own or
control, directly or indirectly, any other corporation, association or business
entity.

            7.4.4. Issuance of Shares. The issuance and delivery of the shares
of Common Stock in accordance with Articles 4.1 and 4.2 of this Research
Agreement have been duly authorized and such shares have been reserved for
issuance, as the case may be, by all necessary corporate action on the part of
CTI, and, when so issued, such shares will be validly issued, fully paid and
non-assessable.

         7.5. Further Representations of NS. NS warrants and represents to CTI
that: (a) NS is an "accredited investor" as that term is used in Rule 501(a)
under the Securities Act in that NS is a corporation and/or an organization
described in Section 501(c)(3) of the Internal Revenue Code with total assets in
excess of $5,000,000; (b) NS is capable of evaluating the risks of owning shares
of CTI' s Common Stock and understands that an investment in CTI involves
substantial risk, possibly including the complete loss of the investment; (c) NS
understands that the shares of CTI's Common Stock it will be issued under this
Agreement have not been registered under the Securities Act of 1933 or any state
securities or "blue sky" laws and that such shares cannot be resold or otherwise
transferred unless registered under all applicable laws or unless an exemption

                                       15
<PAGE>
from registration is available; and (d) NS is acquiring such shares for its own
account for investment, and not with a view to, or for resale in connection
with, the distribution thereof.

                         ARTICLE 8. TERM AND TERMINATION

         8.1. Expiration. Unless terminated earlier pursuant to Article 8.2
below, the term of sponsored research hereunder shall extend for the full
Research Term and the licenses granted hereunder shall extend for the full
License Tenn.

         8.2. Termination for Cause. Upon or after a breach of any material
provision of this Research Agreement by a party (including non-timely payment of
any payment due to NS hereunder), the non-breaching party may terminate this
Research Agreement by giving the breaching party thirty (30) days notice in
writing specifying the breach; providing, however, that such notice of
termination shall not be effective: (1) if the breaching party cures the
specified breach within such thirty (30) day period; or (2) if the specified
breach is not reasonably curable within such thirty (30) day period, and the
breaching party has commenced cure of such breach within the thirty (30) day
period and thereafter has proceeded diligently to cure such breach within a
reasonable time. This Agreement shall automatically terminate upon the
termination of that certain License Agreement between CTI and NS.

         8.3. Effect of Termination. Expiration or termination of this Research
Agreement shall not relieve the parties of any obligation accruing prior to such
expiration or termination. Moreover, the provisions of Articles 6 and 7 shall
survive the expiration or termination of this Research Agreement.

                    ARTICLE 9. INDEMNIFICATION AND INSURANCE

         9.1. Indemnity. CTI shall indemnify and hold NS harmless from and
against any liability, losses, damages, claims, costs and expenses (including
reasonable fees of attorneys and other professionals and court cost) arising
from a product liability claim, action or cause of action related to the sale of
Products or an act of infringement by CTI of a third party's patent, copyright
or trademark in connection with the manufacture, use, sale, storage or
advertising of Products except to the extent that such claims, demands, suits or
causes of action are based upon gross negligence or willful malfeasance by NS
(hereafter collectively called "Claim"). Subject to

                                       16
<PAGE>
the terms and conditions of this Agreement, CTI will have the primary
responsibility for defending against any Claim (whether arising under theories
of negligence, strict liability, tort, product liability or otherwise and
whether or not NS is named as a defendant in such claim, action or cause of
action).

         9.2. Insurance. In accordance with the provisions of Article 9.1 above,
CTI shall arrange for sufficient insurance and/or self-insurance coverage
commencing no later than the First Commercial Sale and, if possible, will name
NS as an additional insured.

                            ARTICLE 10. MISCELLANEOUS

         10.1. Force Majeure. Neither party shall be held liable or responsible
to the other party or be deemed to have defaulted under or breached this
Research Agreement for failure or delay in fulfilling or performing any term of
this Research Agreement when such failure or delay is caused by or results from
cases beyond the reasonable control of the affected party, including, but not
limited to, fire, floods, embargos, war, acts of war (whether war is declared or
not), insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God, or acts, omissions or delays in acting by any
Governmental authority for the other party.

         10.2. Assignment. This Research Agreement may not be assigned or
otherwise transferred by either party without the written consent of the other
party; provided, however, that CTI and its Affiliates may, without such consent,
assign this Research Agreement and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its business
relating to HMG-1 inhibitors and antagonists (including that certain License
Agreement between CTI and NS), or in the event of its merger or consolidation.
Any purported assignment in violation of the preceding sentence shall be void.
Any permitted assignee shall assume all obligations of its assignor under this
Research Agreement. NS shall have the right to sell, assign or otherwise
transfer its entire right, title and interest to the patent applications and/or
patents within NS Patent Rights to an NS Affiliate, provided the Affiliate
assumes all of the obligations of NS hereunder. Otherwise, NS shall not sell,
assign or otherwise transfer title or any portion thereof to any patent
application or patent within the NS Patent Rights as long as exclusive licenses
under that patent application and/or patent are still held by CTI without the
prior written consent of CTI, which consent will not be unreasonably withheld.

                                       17
<PAGE>
         10.3. Severability. Each party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country or
community or association of countries. Should one or more provisions of this
Research Agreement be or become invalid, the parties hereto shall substitute, by
mutual consent, valid provisions for such invalid provisions, which valid
provisions in their economic effect are sufficiently similar to the invalid
provisions that it can be reasonably assumed that the parties would have entered
into this Research Agreement with such valid provisions. In case such valid
provisions cannot be agreed upon, the invalidity of one or several provisions of
this Research Agreement shall not affect the validity of this Research
Agreement, as a whole, unless the invalid provisions are of such essential
importance to this Research Agreement that it is to be reasonably assumed that
the parties would not have entered into this Research Agreement without the
invalid provisions.

         10.4. Notices. Any consent, notice or report required or permitted to
be given or made under this Research Agreement by one of the parties hereto to
the other shall be in writing, delivered personally or by facsimile or courier,
postage prepaid (where applicable), addressed to such other party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor, and shall be effective upon receipt by
the addressee.

            If to CTI:  CRITICAL THERAPEUTICS, INC.
                        c/o HealthCare Ventures LLC
                        One Kendall Square, Building 300, Suite 329
                        Cambridge, Massachusetts 02139

                        Attention: Christopher K. Mirabelli, Ph.D., Acting
                                   President
                        Fax: (617) 252-4342
            If to NS:   NORTH SHORE - LONG ISLAND JEWISH RESEARCH INSTITUTE
                        350 Community Drive
                        Manhasset, New York 11030

                        Attention: Chief Executive Officer
                        Fax: (516) 562-1022

         10.5. Applicable Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York.

                                       18
<PAGE>
         10.6. Dispute Resolution. Any disputes arising between the parties
relating to, arising out of or in any way connected with this Research Agreement
or any term or condition hereof, or the performance by either party of its
obligations hereunder, whether before or after termination of this Research
Agreement, shall be promptly presented to the President of CTI and the Chief
Executive Officer of NS for resolution. If prompt resolution is not reached, the
dispute may be submitted to the American Arbitration Association in New York,
New York for non-binding mediation.

         10.7. Entire Agreement. This Research Agreement contains the entire
understanding of the parties with respect to the subject matter hereof. All
express or implied agreements and understandings, either oral or written,
heretofore made are expressly merged in and made a part of this Research
Agreement. This Research Agreement may be amended, or any term hereof modified,
only by a written instrument duly executed by both parties hereto.

         10.8. Headings. The captions to the several articles hereof are not a
part of this Research Agreement, but are merely guides or labels to assist in
locating and reading the several articles.

         10.9. Independent Contractors. It is expressly agreed that CTI and NS
are independent contractors and that the relationship between the two parties
shall not constitute a partnership, joint venture or agency. Neither CTI nor NS
shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, which shall be binding on the other, without
the prior consent of the other party to do so.

         10.10. Waiver. The waiver of either party hereof of any right hereunder
or the failure to perform or of a breach by the other party shall not be deemed
a waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.

         10.11. Counterparts. This Research Agreement may be executed in two
counterparts, each of which shall be deemed an original, both of which together
shall constitute one and the same instrument.

                                       19
<PAGE>
         10.12. Use of Names. NS and CTI (and its respective Affiliates) each
shall not use the name of the other without prior written consent of the other,
which shall not be unreasonably withheld, except if the use of such name is
required by law, regulation or judicial order, in which event the party
intending to use or using such name will promptly inform the other party of such
required use.

                                       20
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Research Agreement as of the
date set forth below.

<TABLE>
<S>                                                          <C>
CRITICAL THERAPEUTICS, INC.                                  NORTH SHORE - LONG ISLAND JEWISH
                                                             RESEARCH INSTITUTE

By:      /s/ Howland S. Warren, Jr., M.D.                    By:      /s/ Nicholas Chiorazzi
   -----------------------------------------                    ----------------------------
Name:    Howland S. Warren, Jr., M.D.                        Name:    Nicholas Chiorazzi
Title:   Chairman of the Board                               Title:   Director and CEO
Date:    July 2, 2001                                        Date:    June 29, 2001
</TABLE>

Agreed to and Accepted as of the Effective Date

By:     /s/ Kevin J. Tracey
   -----------------------------------
         Kevin J. Tracey, M.D.

                                       21
<PAGE>

                                  ATTACHMENT A

                                  RESEARCH PLAN

                                      [**]
<PAGE>
Year 1

[**] (Year 1).

<Table>
<S>                           <C>                           <C>
Labor                         Wang, Haichao                 [**]
                              Technician (TBN)
Fringe

Supplies                                                    [**]
Subtotal                                                    [**]
Indirect Costs                                              [**]
Total (annual)                                              [**]
Years Running                                               1 year
Total Cost to CTI (year 1)                                  [**]

Total Cost to CTI (years 1 and 2)                           [**]
</Table>

<PAGE>
Year 2

[**] (Year 2).

<Table>
<S>                                <C>                                <S>
Labor                              Haichao, Wang                      [**]
                                   Technician (TBN)                   [**]
Fringe

Supplies                                                              [**]
Subtotal                                                              [**]
Indirect Costs
Total (Annual)                                                        [**]
Years Running                                                         1 year
Total Cost to CTI (Year 2)                                            [**]
</Table>

<PAGE>
                            FIRST AMENDMENT AGREEMENT

         This First Amendment Agreement is made effective July 1, 2003 by and
between Critical Therapeutics, Inc., a Delaware corporation ("CTI") and North
Shore-Long Island Jewish Research Institute, a New York non-profit corporation
("NS").

                                    RECITALS

         WHEREAS, CTI and NS are parties to a Sponsored Research and License
Agreement (the "Research Agreement") having an Effective Date of July 1, 2001,
pursuant to which CTI agreed to sponsor and has sponsored research at NS in the
Field;

         WHEREAS, the Research Agreement provides for further research support
by CTI at NS in the Field upon mutual agreement of the parties; and

         WHEREAS, CTI and NS now mutually desire to continue research support by
CTI at NS in the Field;

         NOW, THEREFORE, in consideration of the mutual covenants contained
herein and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties agree to amend the Research Agreement,
as follows:

1.       Section 1.11 is deleted and replaced with:

         1.11. "Research Plan" shall mean the research program described in
Attachment A to the Research Agreement for the first two years of the Research
Term and the research program described in Attachment A-I (attached hereto) for
years three (3) through five (5) of the Research Term, as revised from time to
time as provided for in this Research Agreement.

2.       Section 1.13 is deleted and replaced with:

         1.13. "Research Term" shall mean the five (5)-year period starting on
the first day of the month following the Effective Date of this Research
Agreement and any extension of this period mutually agreed upon by CTI and NS.
<PAGE>
3.       Section 2.1 is deleted and replaced with:

         2.1. CTI Support. CTI agrees to financially support research at NS in
the Field for the Research Term. The amount of CTI financial support shall be:

<TABLE>
<S>                                                      <C>
           First Research Year                           Two Hundred Thousand Dollars
                                                         ($200,000.00)

           Subsequent Research Year(s)                   To be mutually agreed upon.
</TABLE>

CTI shall make payments of Fifty Thousand Dollars ($50,000.00) to NS in advance
of the commencement of the Research Term and in advance of each three-month
anniversary thereof.

4.       Section 8.4 is added, as follows:

         8.4 Notwithstanding any other provision of this Research Agreement, if
Dr. Kevin J. Tracey ceases full-time employment at NS, or is otherwise unable to
directly supervise the Sponsored Research hereunder, CTI shall have the right to
terminate further financial support to NS pursuant to this Research Agreement
upon ninety (90) days written notice to NS, provided however, that CTI shall
reimburse NS for any non-cancelable monetary commitments made by NS prior to the
notice of termination.

5.       The amendments set forth above shall be deemed to be incorporated into
the Research Agreement in full and to be an integral part thereof as though
fully set forth therein. With the exception of the above amendments, all other
provisions of the Research Agreement shall remain in full force and effect.

         IN WITNESS WHEREOF, the parties hereto have entered into and executed
this First Amendment Agreement on the dates set forth below.

<TABLE>
<S>                                                          <C>
CRITICAL THERAPEUTICS, INC.                                  NORTH SHORE - LONG ISLAND JEWISH
                                                             RESEARCH INSTITUTE

By:   /s/ Paul Rubin                                         By:  /s/ Robin D. Wittenstein
   -----------------------------------------                    --------------------------
Name:    Paul Rubin                                          Name:    Robin D. Wittenstein
Title:   CEO                                                 Title:   VP & COO
</TABLE>
<PAGE>
<TABLE>
<S>                                                          <C>
Date:    7/17/03                                             Date:    7/17/03
</TABLE>

Agreed to and Accepted as of the Effective Date

By:     /s/ Kevin J. Tracey
   -----------------------------------
         Kevin J. Tracey, M.D.

Date:  7/28/03
<PAGE>
                                 ATTACHMENT A-1

27 June 2003

HMGB1 RESEARCH PLAN FOR THE LABORATORY OF BIOMEDICAL SCIENCE (TRACEY LAB) UNDER
THE SPONSORED RESEARCH AGREEMENT WITH CTI

                                      [**]
<PAGE>
                                   EXHIBIT 3.4

    ACCOUNTING OF LICENSE REVENUES UNDER CTI LICENSE AS OF THE EXECUTION DATE

By way of clarification of Section 3.4, the Parties agree that MGH shall receive
[**] Percent ([**]%) of all net License Revenues (that is, MGH shall be paid
[**] Percent ([**]%) of that amount of License Revenues that is net of
stipulated overhead and patent cost recovery), whether such License Revenues
relate to specific claims of the Joint Inventions and Joint Patents or to the
Other Patent Rights or both.

Received:  $[**]    gross License Revenues under the CTI License (the "Down
                    Payment" thereunder)

Less:      $[**]    ([**]% retained by North Shore as administrative overhead)

Net:       $[**]    North Shore      [**]%    $[**]    (+$[**] per above)

                    MGH                [**]%   $  [**]

End of Exhibit 3.4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]